Product Code: 596200605
Price and reimbursement are stopping physicians from prescribing the drugs they want.
In the psoriasis market, brands are gaining or losing market share due to, in many cases, avoidable barriers. There's a clear and huge separation in number of prescriptions between the three market leaders and the remainder of the market.
If barriers did not exist, the playing field would be significantly more level among the drugs with lower market share, and the current strongest player would lose the lead.
The report compares 8 major psoriasis treatments - Humira, Stelara, Enbrel, Remicade, Cosentyx, Inflectra, Remsima, and Otezla. You'll get a detailed picture of what prevents doctors from prescribing your brand, who you're losing market share to, and who you're taking it from.
That's information you can use to win back lost share and compete more effectively.
Get Answers to Key Questions about Psoriasis Drug Brands
- Cosentyx (secukinumab; Novartis) - Which one barrier is most significantly effecting the prescription of this drug? Could it be overcome?
- Humira (adalimumab; AbbVie) - Humira is significantly gaining against the other brands, but which factor is it that makes this the drug of choice?
- Enbrel (etanercept; Pfizer) - Is Enbrel's price point benefiting its uptake or inhibiting it?
- Inflectra (Infliximab, Pfizer) - Which medications are being chosen as substitutes to Inflectra and what is the primary factor causing this?
- Otezla (apremilast; Celgene) - How does Otezla fall within the guidelines and what does this do to prescribing rates as compared to its competitors?
- Remicade (infliximab; MSD) - Remicade has multiple preferential factors, however why is it still losing out to the market leader?
- Remsima (infliximab; Mundipharma/Napp) - What factor is holding Remsima back from winning market share?
- Stelara (ustekinumab; Janssen Biotech) - Which one barrier is causing the biggest loss for Stelara and could it be overcome?
- Of physicians affected by barriers, many cannot prescribe the drugs they actually want: See how inability to reimburse, price, and availability on the formulary are the key inhibitors.
- Fierce competition among top three drugs: the top three drugs are all making gains due to market barriers, but one is starting to outmatch the competition.
- The bottom of the market are losing out most to barriers: Although a close race, a change to the condition of the barriers, or coping strategy could see one drug leave the others behind.
- Losing drugs hold minimal prescription usage: The percentage of the three least prescribed drugs added together is still less than 50% than that of the leading drugs.
- Stability in number of barriers experienced: Contrary to the US, all but one of the EU5 drugs finds that they have a surprisingly similar number of barriers to prescription.
- Opportunity via awareness: Several drugs have the potential to grow market share due to a sizeable percentage of prescribers being unaware of their drugs.
- EU and US landscapes strikingly different: The US sees drugs being inhibited by market barriers circa 50% more when compared to the EU5. See the US report to find out what other key differences there are.
Exploring Market Access Issues
Market Access Impact: psoriasis explores key issues affecting psoriasis drug manufacturers. You'll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest effect?
How barriers affect your brand:
- How many doctors prescribe your brand? How many don't, but would consider it?
- Why don't doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 150 Medical dermatologists -30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.
All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with melanoma in total in the last month
We conducted the survey between January 28th and February 11th, 2016.